All In Biotech

Drug Trial Radar · NCT07765628

A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis

A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HS-20118 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 6, 2026

Primary completion

Feb 28, 2027

Study completion Jul 10, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of HS-20118 compared with placebo in participants with moderate to severe plaque psoriasis.

Conditions

  • Moderate to Severe Plaque Psoriasis

Interventions

  • HS-20118Drug

    Administered orally, once weekly (QW)

  • PlaceboDrug

    Administered orally, once weekly (QW)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving PASI 75 (≥75% improvement from baseline in PASI) at Week 16Time frame: 16 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.